NCT03666988View on ClinicalTrials.gov

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

PHASE1TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

March 4, 2021

Study Completion Date

March 4, 2021

Conditions
Neoplasms
Interventions
DRUG

GSK3368715

GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.

DRUG

GSK3368715

GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .

Trial Locations (9)

3000

GSK Investigational Site, Melbourne

28050

GSK Investigational Site, Madrid

77030

GSK Investigational Site, Houston

84112

GSK Investigational Site, Salt Lake City

90033

GSK Investigational Site, Los Angeles

92663

GSK Investigational Site, Newport Beach

19104-4206

GSK Investigational Site, Philadelphia

M5G 1X5

GSK Investigational Site, Toronto

08035

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03666988 - First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter